Answers are grounded in this paper and cite their sources.
Interview with Dr. Alice Shaw on a new model for accelerating the development of promising oncology drugs. (10:06)Download Increasingly, firms developing cancer drugs are forgoing standard phased development for a seamless approach of adding cohorts to a first-in-human trial to study doses and activity in various cancers. Key regulatory interactions and protections may therefore be missing.
No takes yet. Share an insight, caveat, or question.
Prowell et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: